Results 11 to 20 of about 15,616 (165)

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

EClinicalMedicine, 2022
Summary: Background: Currently, there is no US Food and Drug Administration approved therapy for patients with pleural mesothelioma who have relapsed following platinum-doublet based chemotherapy. Vinorelbine has demonstrated useful clinical activity in
Dean A. Fennell, Catharine Porter, Jason Lester, Sarah Danson, Paul Taylor, Michael Sheaff, Robin M Rudd, Aarti Gaba, Sara Busacca, Lisette Nixon, Georgina Gardner, Liz Darlison, Charlotte Poile, Cathy Richards, Peter-Wells Jordan, Gareth Griffiths, Angela Casbard   +16 more
doaj   +1 more source

Risk factors for venous irritation in patients receiving vinorelbine: a retrospective study

Journal of Pharmaceutical Health Care and Sciences, 2018
Background Vinorelbine is known to be effective in the treatment of non-small cell lung cancer and breast cancer. However, venous irritation is a common side effect.
Yoshihito Morimoto, Kumika Miyawaki, Reisuke Seki, Kazuhiro Watanabe, Masayoshi Hirohara, Takao Shinohara   +5 more
doaj   +1 more source

Unforeseen cytomegalovirus retinopathy following high dose thiotepa and proton irradiation in a pediatric patient with high-risk medulloblastoma: A case report

Frontiers in Pediatrics, 2023
In immunocompetent individuals, cytomegalovirus (CMV) infection is usually mild but may cause severe complications such as retinitis, pneumonitis, and encephalitis in immunocompromised individuals.
Elisabetta Bigagli, Sara Agostiniani, Alessandra Pugi, Barbara Rombi, Elena Eve Tornaboni, Maria Luigia Censullo, Carlotta Gemma Gori, Rossana Pavone, Iacopo Sardi   +8 more
doaj   +1 more source

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC

Asian Journal of Oncology, 2022
Introduction There are a substantial number of lung cancer patients with negative mutations in Indonesia. This type of cancer is deemed to be the major contributor of lung cancer patient’s death.
Laksmi Wulandari, Gatot Soegiarto, Anna Febriani, Farah Fatmawati, Wirya Sastra Amran   +4 more
doaj   +1 more source

Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis

Cancer Medicine, 2023
Background Patients with alveolar rhabdomyosarcoma (ARMS) have inferior outcomes compared to patients with embryonal rhabdomyosarcoma (ERMS) and more effective chemotherapy options are needed for these patients.
Wendy Allen‐Rhoades, Philip J. Lupo, Michael E. Scheurer, Yueh‐Yun Chi, John F. Kuttesch, Rajkumar Venkatramani, William H. Meyer, Leo Mascarenhas   +7 more
doaj   +1 more source

Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price

Фармакоэкономика, 2021
Objective: comparative assessment of the economic effect of oral vinorelbine when used as indicated, taking into consideration the new registered price.Material and methods.
D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov   +2 more
doaj   +1 more source

Microtubule disruption reduces metastasis more effectively than primary tumor growth

Breast Cancer Research, 2022
Clinical cancer imaging focuses on tumor growth rather than metastatic phenotypes. The microtubule-depolymerizing drug, Vinorelbine, reduced the metastatic phenotypes of microtentacles, reattachment and tumor cell clustering more than tumor cell ...
Keyata N. Thompson, Julia A. Ju, Eleanor C. Ory, Stephen J. P. Pratt, Rachel M. Lee, Trevor J. Mathias, Katarina T. Chang, Cornell J. Lee, Olga G. Goloubeva, Patrick C. Bailey, Kristi R. Chakrabarti, Christopher M. Jewell, Michele I. Vitolo, Stuart S. Martin   +13 more
doaj   +1 more source

Non-linear Dose Response of Lymphocyte Cell Lines to Microtubule Inhibitors

Frontiers in Pharmacology, 2019
Microtubule (MT) inhibitors show anti-cancer activity in a wide range of tumors in vitro and demonstrate high clinical efficacy. To date they are routinely included into many chemotherapeutic regimens.
Daria M. Potashnikova, Daria M. Potashnikova, Aleena A. Saidova, Aleena A. Saidova, Anna V. Tvorogova, Anna V. Tvorogova, Eugene V. Sheval, Ivan A. Vorobjev, Ivan A. Vorobjev, Ivan A. Vorobjev   +9 more
doaj   +1 more source

PERORAL FORMS OF CYTOSTATIC DRUGS IN THERAPY OF METASTATIC MAMMARY GLAND CANCER: ROLE IN CLINICAL PRACTICE

Медицинский совет, 2016
Modern therapeutic approaches allow achieving stable therapeutic effect, extension and maximum long-term preservation of the quality of life of metastatic mammary gland cancer patients.
G. M. TELETAEVA, T. Y. SEMIGLAZOVA, А. S. ZHABINA, D. H. LATIPOVA, V. V. KLIMENKO, Z. S. KOTOVA, A. I. SEMENOVA, S. A. PROTSENKO, V. V. SEMIGLAZOV   +8 more
doaj   +1 more source

Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy

EBioMedicine, 2018
Ectopic pregnancies complicate 1–2 pregnancies and are a leading cause of maternal death. An effective oral drug therapy that replaces surgery might make its treatment safer, cheaper, simpler and therefore more widely accessible. The only current medical
Roxanne Hastie, Elgene Lim, Pavel Sluka, Lisa Campbell, Andrew W. Horne, Lenore Ellett, Natalie J. Hannan, Fiona Brownfoot, Tu'uhevaha J. Kaitu'u-Lino, Stephen Tong   +9 more
doaj   +1 more source